Dihydroergocryptine

Drug #882

Dihydroergocryptine used in the symptomatic treatment of mental deterioration associated with cerebrovascular insufficiency and in peripheral vascular disease

← Previous drug Next drug →

Primary Characteristics

It is of Synthetic origin and belongs to Ergot Alkaloid.

It is classified in Ergot Alkaloid pharmacological group. It is also classified under Psychotherapeutic Drugs .

Molecular Weight: 673.8 · Solubility in Water: null · Solubility in Alcohol: null · Non-proprietary name: Dihydroergocryptine.

Molecular structure of Dihydroergocryptine

Pharmacokinetics

Elimination: plasma half-life is 12-16 hr.

Indications

Dihydroergocryptine is primarily indicated in conditions like Cerebro-vascular insufficiency, Chronic venous insufficiency, Ischaemic heart disease, Migraine, Parkinsonism.

Dihydroergocryptine is also indicated for secondary conditions like Behavioural disorders, Lactation inhibition, Peripheral vascular disease, Psychiatric disease, Raynaud's disease.

Contraindications

Dihydroergocryptine is contraindicated in conditions like Psychosis, Hypersensitivity to the drug.

Dosage

Dihydroergocryptine's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
90 mg	90 mg	—		Maintainance doses for parkinsoinism.
20 mg	20 mg	Every 24h	PO	For migraine
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

None recorded.

Side Effects

Dihydroergocryptine is known to cause more or less tolerable side effects which are usually transient. These include Nausea.

Warnings / Precautions

There is evidence that exposure to Dihydroergotamine (a migraine drug) during pregnancy to give a teratogenic effect on the fetus. A teratogen is a substance that can cause birth defects. The likelihood and severity of the defects may be influenced by the level of exposure and the stage of pregnancy at which exposure occurred.

Available Brands

Click on a strength to view available brands.

Multi-Ingredient Combinations

Oral Soln

1 mg/ml

Storage Conditions

Dihydroergocryptine should be stored .

Drug Classification

1.12.8 — Other cardiovascular preparations

Manufacturers

Manufacturers of Dihydroergocryptine in Pakistan:

Chiesi Zafa